The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -686,425 | -1,295,365 | -712,184 | -1,292,788 |
| Stock-based compensation | - | 0 | 0 | 23,385 |
| Non-cash lease expense | 159 | 237 | 238 | 317 |
| Prepaid expense and other assets | - | -16,288 | - | - |
| Prepaid expenses | 13,835 | - | -4,597 | 4,230 |
| Accounts payable and other current liabilities | -384,781 | 678,042 | -53,896 | -595,644 |
| Net cash flows from operating activities | -1,084,515 | -601,165 | -761,245 | -1,868,960 |
| Net change in cash and cash equivalents | -1,084,515 | -601,165 | -761,245 | -1,868,960 |
| Cash and cash equivalents at beginning of period | 2,375,493 | 2,976,658 | 5,606,863 | - |
| Cash and cash equivalents at end of period | 1,290,978 | 2,375,493 | 2,976,658 | - |
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)